Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Drug Notebook

FDA Alerts

    Abuse Potential
  • Schedule II controlled substance with abuse liability similar to other opiates.
  • Potential for abuse in a manner similar to other legal or illicit opiates. Consider abuse potential when prescribing or dispensing morphine sulfate extended-release capsules (Kadian®) in situations where the clinician or pharmacist is concerned about increased risk of misuse, abuse, or diversion.

    Overdose Risk with Improper Administration of Extended-release (Modified-, Controlled-, or Sustained-release) Products
  • Extended-release preparations (Avinza®, Kadian®, MS Contin®, Oramorph® SR) are indicated for relief of moderate to severe pain requiring continuous, around-the-clock opiate therapy for an extended period of time.
  • Extended-release formulations are to be swallowed whole; alternatively the contents of Avinza® or Kadian® capsules may be sprinkled on applesauce.
  • Extended-release capsules (e.g., Kadian®) are not intended for use as an as-needed (“prn”) analgesic.
  • Chewing, crushing, or dissolving any of these extended-release preparations (including capsule beads or pellets) could result in rapid release and absorption of a potentially fatal dose of morphine.
  • Do not consume alcoholic beverages or prescription or nonprescription preparations containing alcohol during therapy with extended-release capsules (Avinza®, Kadian®). Consuming alcohol while receiving extended-release capsules could result in rapid release and absorption of a potentially fatal dose of morphine.

Media Gallery
Drug Info Tools
Search by color, shape and markings. click here
Check any 2 drugs for interactions. click here
Compare any two drugs side by side. click here
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
morphine
(MOR feen)
P F / MI 15 | 15 mgP F / MI 15   15 mg
bottle, 100 each Morphine SO4 15mg, Oral tablet, white, round-shaped, scored, side 1:P F, side 2:MI 15
P F / MI 30 | 30 mgP F / MI 30   30 mg
bottle, 100 each Morphine SO4 30mg, Oral tablet, white, oblong-shaped, scored, side 1:P F, side 2:MI 30
54 733 | 15 mg54 733   15 mg
box, 4 unit dose strips, 25 each Morphine SO4 15mg, Oral tablet, white, round-shaped, scored, side 1:54 733
54 733 | 15 mg54 733   15 mg
bottle, 100 each Morphine SO4 15mg, Oral tablet, white, round-shaped, scored, side 1:54 733
54 262 | 30 mg54 262   30 mg
bottle, 100 each Morphine SO4 30mg, Oral tablet, white, round-shaped, scored, side 1:54 262
54 262 | 30 mg54 262   30 mg
box, 4 unit dose strips, 25 each Morphine SO4 30mg, Oral tablet, white, round-shaped, scored, side 1:54 262
ETHEX / 30 | 30 mgETHEX / 30   30 mg
bottle, 100 each Morphine SO4 30mg, Oral tablet, brown, oblong-shaped, scored, side 1:ETHEX, side 2:30
ETH / 15 | 15 mgETH / 15   15 mg
bottle, 100 each Morphine SO4 15mg, Oral tablet, brown, round-shaped, notched, side 1:ETH, side 2:15
Back to Top